Regarding tocilizumab, Cheng et al. demonstrated that it was a powerful IL-6 inhibitor effective in reducing the symptoms associated with CRS in four patients undergoing CAR-T therapy. This evidence concerns the gene IL6 and congenital rubella syndrome.